Amlodipine increases endothelial nitric oxide release by modulating binding of native eNOS protein complex to caveolin-1

European Journal of Pharmacology

Volumn 659, Issue 2-3, 2011, Pages 206-212

  Sharma, Arpeeta ^a,b   Trane, Andy ^a,b   Yu, Carol ^a,b   Jasmin, Jean Francois ^c   Bernatchez, Pascal ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Amlodipine; Caveolae; Caveolin; Endothelium; Nitric oxide

Indexed keywords

AMLODIPINE; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE TRANSFERASE; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COW; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME RELEASE; INTRACELLULAR SIGNALING; MODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TRANSPORT;

AMLODIPINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CATTLE; CAVEOLIN 1; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOTHELIAL CELLS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN BINDING;

EID: 79955932806     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.028     Document Type: Article

References (29)

1. Alexander, J.J., Miguel, R., Piotrowski, J.J., 1993. The effect of nifedipine on lipid and monocyte infiltration of the subendothelial space. J. Vasc. Surg. 17, 841-847 (discussion 847-848).
2. Batova, S., DeWever, J., Godfraind, T., Balligand, J.L., Dessy, C., Feron, O., 2006. The calcium channel blocker amlodipine promotes the unclamping of eNOS from caveolin in endothelial cells. Cardiovasc. Res. 71, 478-485.
3. Bernatchez, P.N., Bauer, P.M., Yu, J., Prendergast, J.S., He, P., Sessa, W.C., 2005. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc. Natl. Acad. Sci. U. S. A. 102, 761-766.
4. Bernatchez, P.N., Acevedo, L., Fernandez-Hernando, C., Murata, T., Chalouni, C., Kim, J., Erdjument-Bromage, H., Shah, V., Gratton, J.P., McNally, E.M., Tempst, P., Sessa, W.C., 2007. Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J. Biol. Chem. 282, 30745-30753.
5. Brouet, A., Sonveaux, P., Dessy, C., Moniotte, S., Balligand, J.L., Feron, O., 2001. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ. Res. 89, 866-873.
6. Chou, T.C., Li, C.Y., Yen, M.H., Ding, Y.A., 1999. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process. Biochem. Pharmacol. 58, 1657-1663.
7. Darblade, B., Caillaud, D., Poirot, M., Fouque, M., Thiers, J.C., Rami, J., Bayard, F., Arnal, J.F., 2001. Alteration of plasmalemmal caveolae mimics endothelial dysfunction observed in atheromatous rabbit aorta. Cardiovasc. Res. 50, 566-576.
8. Dhein, S., Salameh, A., 1999. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 100, 1011. (Pubitemid 29407184)
9. Garcia-Cardena, G., Oh, P., Liu, J., Schnitzer, J.E., Sessa, W.C., 1996. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc. Natl. Acad. Sci. U. S. A. 93, 6448-6453.
10. Garcia-Cardena, G., Martasek, P., Masters, B.S., Skidd, P.M., Couet, J., Li, S., Lisanti, M.P., Sessa, W.C., 1997. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo. J. Biol. Chem. 272, 25437-25440.
11. Gelinas, D.S., Bernatchez, P.N., Rollin, S., Bazan, N.G., Sirois, M.G., 2002. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br. J. Pharmacol. 137, 1021-1030.
12. Gratton, J.P., Fontana, J., O'Connor, D.S., Garcia-Cardena, G., McCabe, T.J., Sessa, W.C., 2000. Reconstitution of an endothelial nitric-oxide synthase (eNOS), hsp90, and caveolin-1 complex in vitro. Evidence that hsp90 facilitates calmodulin stimulated displacement of eNOS from caveolin-1. J. Biol. Chem. 275, 22268-22272.
13. Julius, S., 1988. Amlodipine in hypertension: an overview of the clinical dossier. J. Cardiovasc. Pharmacol. 12 (Suppl 7), S27-S33.
14. Kahn, M.B., Boesze-Battaglia, K., Stepp, D.W., Petrov, A., Huang, Y., Mason, R.P., Tulenko, T.N., 2005. Influence of serum cholesterol on atherogenesis and intimal hyperplasia after angioplasty: inhibition by amlodipine. Am. J. Physiol. Heart Circ. Physiol. 288, H591-H600.
15. Linder, A.E., McCluskey, L.P., Cole III, K.R., Lanning, K.M., Webb, R.C., 2005. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J. Pharmacol. Exp. Ther. 314, 9-15.
16. Liu, J., Garcia-Cardena, G., Sessa, W.C., 1996. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry 35, 13277-13281. (Pubitemid 26349419)
17. Mason, R.P., Moisey, D.M., Shajenko, L., 1992. Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer. Mol. Pharmacol. 41, 315-321.
18. Mason, R.P., Walter, M.F., Trumbore, M.W., Olmstead Jr., E.G., Mason, P.E., 1999. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J. Mol. Cell. Cardiol. 31, 275-281.
19. Morel, N., Godfraind, T., 1994. Selective interaction of the calcium antagonist amlodipine with calcium channels in arteries of spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 24, 524-533.
20. Packer, M., O'Connor, C.M., Ghali, J.K., Pressler, M.L., Carson, P.E., Belkin, R.N., Miller, A.B., Neuberg, G.W., Frid, D., Wertheimer, J.H., Cropp, A.B., DeMets, D.L., 1996. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N. Engl. J. Med. 335, 1107-1114.
21. Pitt, B., Byington, R.P., Furberg, C.D., Hunninghake, D.B., Mancini, G.B., Miller, M.E., Riley, W., 2000. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 102, 1503-1510.
22. Rosenkranz, A.C., Lob, H., Breitenbach, T., Berkels, R., Roesen, R., 2006. Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur. J. Pharmacol. 529, 55-62.
23. Smart, E.J., Ying, Y.S., Mineo, C., Anderson, R.G., 1995. A detergent-free method for purifying caveolae membrane from tissue culture cells. Proc. Natl. Acad. Sci. U. S. A. 92, 10104-10108.
24. Sowa, G., Pypaert, M., Sessa, W.C., 2001. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proc. Natl. Acad. Sci. U. S. A. 98, 14072-14077.
25. Sowa, G., Pypaert, M., Fulton, D., Sessa, W.C., 2003. The phosphorylation of caveolin-2 on serines 23 and 36 modulates caveolin-1-dependent caveolae formation. Proc. Natl. Acad. Sci. U. S. A. 100, 6511-6516.
26. Turgan, N., Habif, S., Kabaroglu, C.G., Mutaf, I., Ozmen, D., Bayindir, O., Uysal, A., 2003. Effects of the calcium channel blocker amlodipine on serum and aortic cholesterol, lipid peroxidation, antioxidant status and aortic histology in cholesterol-fed rabbits. J. Biomed. Sci. 10, 65-72.
27. Yoshida, J., Ishibashi, T., Yang, M., Nishio, M., 2010. Amlodipine, a Ca2+ channel blocker, suppresses phosphorylation of epidermal growth factor receptor in human epidermoid carcinoma A431 cells. Life Sci. 86, 124-132.
28. Yoshii, T., Iwai, M., Li, Z., Chen, R., Ide, A., Fukunaga, S., Oshita, A., Mogi, M., Higaki, J., Horiuchi, M., 2006. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens. Res. 29, 457-466.
29. Zhang, X.P., Loke, K.E., Mital, S., Chahwala, S., Hintze, T.H., 2002. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J. Cardiovasc. Pharmacol. 39, 208-214.